bilaterals.org logo
bilaterals.org logo

medicines


Trump will insist NHS pays more for drugs in trade deal, says ambassador
Donald Trump will put the interests of corporate America first and demand that the NHS pays higher prices for US drugs in a free-trade deal with the UK, the outgoing British ambassador to Washington said.
Phase 1 US China trade deal: patent provisions
China agreed to extend patent terms for novel drugs "to compensate for unreasonable delays that occur in granting the patent or during pharmaceutical product marketing approvals."
India, Indonesia negotiating economic cooperation agreement
India and Indonesia are set to launch negotiations for a Comprehensive Economic Cooperation Agreement (CECA) to cover economic cooperation while trading in goods, services, and investments.
Blueprint for a human rights impact assessment of the planned comprehensive free trade agreement between EFTA and Mercosur
This study assesses the impact of the EFTA-Mercosur free trade agreement on access to medicines, indigenous rights and women rights.
Mexico sees progress in talks to revise USMCA, says drug protections to ease
Mexico’s government said progress was being made toward revising a new North American trade pact that will sharply reduce protections for biologic drugs.
Trump administration considers loosening drug protections in USMCA
Generic versions of biologic drugs could come to market faster.
How to protect the NHS in a post-Brexit trade deal with the US
There are two solutions to this impending problem, which most political parties could agree to if they are truly committed to protecting the NHS.
New AFTINET fact sheet: The impact of trade and investment rules on public health
Trading away our health: How trade and investment rules put corporate rights ahead of public health.
As Modi visits US, what does the free trade pact mean for India’s pharma industry?
A Free Trade Agreement with the US will likely result in the amendment of the Patents Act, which could impact the Indian pharma industry.
US farmers’ group says pharma, not dairy, is main obstacle to ratifying USMCA
The National Farmers Union says the new deal’s extended patent protection for new pharmaceuticals must be reduced so that less expensive generic versions of new drugs can be available to consumers sooner.
EU-US trade talks: milestone reached in mutual recognition on pharmaceuticals
The mutual recognition agreement for inspections of manufacturing sites for human medicines in their respective territories can make it faster and less costly for both sides to bring medicines to the market.
Old wine in new bottles: Keep TRIPS-plus provisions out of the RCEP FTA!
Intellectual property barriers, which would hinder access to affordable medicines, have supposedly been removed from the draft RCEP free-trade agreement (FTA).
India protects drug, agriculture business at RCEP
Three harmful provisions concerning pharmaceuticals and agriculture which were part of the RCEP have been withdrawn.
Thai CSOs’ proposition against IP enforcement in the RCEP negotiation
FTA Watch would like to urge the Thai negotiation team for the RCEP to have a strong position to reject proposals on Intellectual Property Enforcement chapter.
NAFTA bill lets Trudeau cabinet wait and see what US Congress does Social Sharing
US Democrats fear higher drug prices, trying to change text of trade deal
Free trade can seriously damage your health
These practises open the door to Big Pharma companies and disastrous private health companies.
Will free trade make Africans sick?
African governments must act immediately to address the AfCFTA’s potential negative implications for Africans’ health.
2019: USTR takes aim at European countries over pharmaceutical pricing and reimbursement policies
In its latest report on foreign trade barriers, the USTR, prompted by the pharmaceutical industry, takes aim at the pharmaceutical pricing and reimbursement policies in the European Union.
PBO report shows that new NAFTA provisions threaten Pharmacare, says Council of Canadians
The Parliamentary Budget Officer (PBO) revealed that new intellectual property provisions in the Canada-United States-Mexico Agreement would cost Canadians as much as $169 million more per year for pharmaceutical drugs
Trump’s NAFTA 2.0 puts big pharma first, America second
The new version of NAFTA forbids the US Congress from curtailing Big Pharma’s patent monopolies on some of the world’s most expensive drugs.